Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. Ivosidenib is an isocitrate dehydrogenase-1 inhibitor that works by decreasing abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to differentiation of malignant cells.
Read the full article on WikipediaLocally advanced or metastatic cholangiocarcinoma Clinical criteria: Patient must have a test of tumour tissue confirming the presence of an IDH1 R132 variant, AND Patient must have had systemic therapy for this condition prior to initiating treatment with this drug for this condition, AND Patient must have/have had a WHO performance status of 2 or less at treatment initiation with this drug, AND The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition. Confirm that evidence of the presence of a pathogenic variant of the IDH1 gene is documented/retained in the patient's medical records once only with the first PBS prescription.
Working under the parallel aged-care framework? Aged-care equivalent →